INTRODUCTION: The objective of this study is to determine if change in acetylcholine receptor antibody (AChR-ab) levels reflects change in clinical severity in patients with myasthenia gravis (MG). METHODS: We reviewed results from a prospective trial in MG and from all 85 patients in an MG Clinic who had AChR-ab determinations performed at least twice by the same commercial laboratory. RESULTS: Change in AChR-ab levels correlated only weakly with change in clinical severity. AChR-ab levels fell in 92% of patients who improved and in 63% who did not. A fall in AChR-ab level had a positive predictive value for clinical improvement of 83% and a negative predictive value of only 59%. CONCLUSIONS: AChR-ab levels fell in almost all patients who improved, but also in most patients who did not. Thus, we do not recommend commercially available AChR-ab levels as a biomarker of improvement in MG. However, antibody levels might be useful as a marker for inadequate immunotherapy.
INTRODUCTION: The objective of this study is to determine if change in acetylcholine receptor antibody (AChR-ab) levels reflects change in clinical severity in patients with myasthenia gravis (MG). METHODS: We reviewed results from a prospective trial in MG and from all 85 patients in an MG Clinic who had AChR-ab determinations performed at least twice by the same commercial laboratory. RESULTS: Change in AChR-ab levels correlated only weakly with change in clinical severity. AChR-ab levels fell in 92% of patients who improved and in 63% who did not. A fall in AChR-ab level had a positive predictive value for clinical improvement of 83% and a negative predictive value of only 59%. CONCLUSIONS: AChR-ab levels fell in almost all patients who improved, but also in most patients who did not. Thus, we do not recommend commercially available AChR-ab levels as a biomarker of improvement in MG. However, antibody levels might be useful as a marker for inadequate immunotherapy.
Authors: Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn Journal: Front Immunol Date: 2017-05-31 Impact factor: 7.561
Authors: Olaia F Vila; Miguel Chavez; Stephen P Ma; Keith Yeager; Lyandysha V Zholudeva; Jennifer M Colón-Mercado; Yihuai Qu; Trevor R Nash; Carmen Lai; Carissa M Feliciano; Matthew Carter; Roger D Kamm; Luke M Judge; Bruce R Conklin; Michael E Ward; Todd C McDevitt; Gordana Vunjak-Novakovic Journal: Biomaterials Date: 2021-07-30 Impact factor: 15.304
Authors: Michele M Tana; Zakera Shums; Jay Milo; Gary L Norman; Patrick S Leung; M Eric Gershwin; Mazen Noureddin; David E Kleiner; Xiongce Zhao; Theo Heller; Jay H Hoofnagle Journal: Am J Clin Pathol Date: 2015-10 Impact factor: 2.493
Authors: Bettina Schreiner; Burkhard Becher; Florian Ingelfinger; Sinduya Krishnarajah; Michael Kramer; Sebastian G Utz; Edoardo Galli; Mirjam Lutz; Pascale Zwicky; Ayse U Akarca; Nicole Puertas Jurado; Can Ulutekin; David Bamert; Corinne C Widmer; Luca Piccoli; Federica Sallusto; Nicolás G Núñez; Teresa Marafioti; Didier Schneiter; Isabelle Opitz; Antonio Lanzavecchia; Hans H Jung; Donatella De Feo; Sarah Mundt Journal: Acta Neuropathol Date: 2021-03-28 Impact factor: 17.088
Authors: Jeffrey T Guptill; John S Yi; Donald B Sanders; Amanda C Guidon; Vern C Juel; Janice M Massey; James F Howard; Flavia Scuderi; Emanuela Bartoccioni; Amelia Evoli; Kent J Weinhold Journal: Neurol Neuroimmunol Neuroinflamm Date: 2015-02-26
Authors: Vera Bril; Michael Benatar; Henning Andersen; John Vissing; Melissa Brock; Bernhard Greve; Peter Kiessling; Franz Woltering; Laura Griffin; Peter Van den Bergh Journal: Neurology Date: 2020-11-20 Impact factor: 9.910